Series A-1 Warrants (October 2024 private placement)
Issued 2024
Shares Underlying
Exercise Price
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
DilutionScan read 45 of Inhibikase Therapeutics, Inc.'s SEC filings and found 21 warrant series, 2 ATM programs, 4 shelf registrations and 5 completed offerings on file for IKT. The latest dilution event on file is ATM sales on Jul 31, 2026. Analysis updated Nov 1, 2026.
Raise routes on file: active ATM + effective shelf · latest dilution event 95 days ago
The dominant contractual driver and its mechanism, then each further driver ranked.
Jul 31, 2026 · ATM Sale
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Shares outstanding, potential dilution and cash over time
Issued 2024
Shares Underlying
Exercise Price
Issued 2024
Shares Underlying
Exercise Price
Issued 2024
Shares Underlying
Exercise Price
Issued 2025
Shares Underlying
Exercise Price
Issued 2026
Shares Underlying
Exercise Price
Issued 2024
Shares Underlying
Exercise Price
Issued 2024
Total capacity
Sold to date
Issued 2025
Total capacity
Sold to date
Issued 2025
Total capacity
Remaining
Issued 2024
Total capacity
Remaining
Issued 2025
Total capacity
Remaining
Issued 2022
Total capacity
Remaining
Issued 2025
Gross proceeds
Price per share
Gross proceeds
Price per share
Issued 2026
Gross proceeds
Price per share
Gross proceeds
Price per share
Gross proceeds
Price per share
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
DilutionScan ProEvery instrument in full · $59/mo
Covered companies in Biotechnology. All tickers A to Z